RU2316347C2 - Композиция для стимуляции иммунного ответа (варианты), способы ее получения, применения и способы стимуляции иммунного ответа с использованием этих композиций - Google Patents

Композиция для стимуляции иммунного ответа (варианты), способы ее получения, применения и способы стимуляции иммунного ответа с использованием этих композиций Download PDF

Info

Publication number
RU2316347C2
RU2316347C2 RU2004102520/13A RU2004102520A RU2316347C2 RU 2316347 C2 RU2316347 C2 RU 2316347C2 RU 2004102520/13 A RU2004102520/13 A RU 2004102520/13A RU 2004102520 A RU2004102520 A RU 2004102520A RU 2316347 C2 RU2316347 C2 RU 2316347C2
Authority
RU
Russia
Prior art keywords
oil
hcv
antigen
immune response
composition
Prior art date
Application number
RU2004102520/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2004102520A (ru
Inventor
Майкл ХОТОН (US)
Майкл ХОТОН
Стефен Р. КОУТС (US)
Стефен Р. КОУТС
Дерек О`ХЭЙГАН (US)
Дерек О`ХЭЙГАН
Ю-Лиан ФОНГ (US)
Ю-Лиан ФОНГ
Original Assignee
Чирон Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чирон Корпорейшн filed Critical Чирон Корпорейшн
Publication of RU2004102520A publication Critical patent/RU2004102520A/ru
Application granted granted Critical
Publication of RU2316347C2 publication Critical patent/RU2316347C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2004102520/13A 2001-06-29 2002-06-28 Композиция для стимуляции иммунного ответа (варианты), способы ее получения, применения и способы стимуляции иммунного ответа с использованием этих композиций RU2316347C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30222701P 2001-06-29 2001-06-29
US60/302,227 2001-06-29

Publications (2)

Publication Number Publication Date
RU2004102520A RU2004102520A (ru) 2005-06-10
RU2316347C2 true RU2316347C2 (ru) 2008-02-10

Family

ID=23166848

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004102520/13A RU2316347C2 (ru) 2001-06-29 2002-06-28 Композиция для стимуляции иммунного ответа (варианты), способы ее получения, применения и способы стимуляции иммунного ответа с использованием этих композиций

Country Status (12)

Country Link
US (3) US20030138458A1 (https=)
EP (1) EP1572124A4 (https=)
JP (2) JP4370161B2 (https=)
CN (2) CN1931365A (https=)
AU (1) AU2002322358B2 (https=)
CA (1) CA2451739A1 (https=)
CZ (1) CZ20033515A3 (https=)
HU (1) HUP0400346A2 (https=)
NZ (1) NZ530632A (https=)
RU (1) RU2316347C2 (https=)
SK (1) SK15762003A3 (https=)
WO (1) WO2003002065A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2677639C2 (ru) * 2012-07-13 2019-01-18 Шин Ниппон Биомедикал Лэбораториз, Лтд. Хиральный адъювант нуклеиновой кислоты
RU2812477C2 (ru) * 2017-04-27 2024-01-30 Иммусофт Корпорейшн В-клетки для доставки терапевтических средств in vivo и их дозы

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CZ20033515A3 (cs) * 2001-06-29 2005-01-12 Chiron Corporation Kompozice vakcíny HCV E1E2
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
PT2241325E (pt) * 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
EP1578954A4 (en) 2002-12-11 2010-08-11 Coley Pharm Group Inc 5'-CPG NUCLEIC ACIDS AND USE METHOD
US20050191358A1 (en) * 2003-01-14 2005-09-01 Derek O' Hagan Microparticles with adsorbed polynucleotide-containing species
CA2523266A1 (en) * 2003-04-25 2004-11-11 Chiron Corporation Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
EP1631264B8 (en) * 2003-06-02 2017-05-24 GlaxoSmithKline Biologicals SA Immunogenic compositions based on microparticles comprising adsorbed toxoid and a polysaccharide-containing antigen
NZ551319A (en) * 2004-05-17 2010-07-30 Novartis Vaccines & Diagnostic Truncated Hepatitis C virus NS5 domain and fusion proteins comprising same
FR2878746B1 (fr) 2004-12-02 2007-02-23 Vetoquinol Sa Sa Nouvelle composition pharmaceutique utilisable dans le domaine des vaccins
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
AU2015234338C1 (en) * 2006-07-28 2017-07-20 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
US8324369B2 (en) * 2007-11-30 2012-12-04 Baylor College Of Medicine Dendritic cell vaccine compositions and uses of same
RU2572826C2 (ru) 2008-12-02 2016-01-20 Чиралджен, Лтд. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
WO2011040535A1 (ja) 2009-09-30 2011-04-07 東レ株式会社 Ｃ型肝炎ウイルスワクチン組成物
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
AU2012284265B2 (en) 2011-07-19 2017-08-17 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
JP6453212B2 (ja) 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． キラル制御
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
JP2016520077A (ja) * 2013-05-15 2016-07-11 ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ Ｅ１ｅ２ｈｃｖワクチン及び使用方法
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
AU2017341735B2 (en) 2016-10-11 2022-01-13 Helmholtz Center for Infection Research Hepatitis C virus immunogenic compositions comprising as an adjuvant a cyclic dinucleotide or an archaeosome and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2136311C1 (ru) * 1991-09-13 1999-09-10 Чирон Корпорейшн Иммуногенная полипептидная композиция, способ получения композиции, способ продуцирования и способ обнаружения антител, набор
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
ATE509102T1 (de) * 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU3241095A (en) * 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
BR9506059A (pt) * 1994-07-29 1997-10-28 Innogenetics Nv Proteinas envelopes purificadas de virus c para uso de diagnóstico e terapêutico
GB9703406D0 (en) * 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
ES2175668T3 (es) * 1997-12-16 2002-11-16 Chiron Corp Uso de microparticulas combinadas con emulsiones de aceite en agua submicronicas.
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
DE60014076T2 (de) 1999-04-19 2005-10-13 Glaxosmithkline Biologicals S.A. Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
SK287400B6 (sk) * 1999-09-25 2010-08-09 University Of Iowa Research Foundation Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
DE60043708D1 (de) * 1999-10-13 2010-03-04 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen
EP1239876B1 (en) * 1999-11-19 2008-07-30 Csl Limited Hcv vaccine compositions
JP2004500366A (ja) * 1999-12-01 2004-01-08 カイロン　コーポレイション Ｃ型肝炎ウイルス（ｈｃｖ）について特異的な抗体を誘発すること
ATE350015T1 (de) * 2000-09-28 2007-01-15 Novartis Vaccines & Diagnostic Mikropartikelzusammensetzungen und verfahren zu ihrer herstellung
CZ20033515A3 (cs) * 2001-06-29 2005-01-12 Chiron Corporation Kompozice vakcíny HCV E1E2
AU2003299994A1 (en) * 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2136311C1 (ru) * 1991-09-13 1999-09-10 Чирон Корпорейшн Иммуногенная полипептидная композиция, способ получения композиции, способ продуцирования и способ обнаружения антител, набор
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2677639C2 (ru) * 2012-07-13 2019-01-18 Шин Ниппон Биомедикал Лэбораториз, Лтд. Хиральный адъювант нуклеиновой кислоты
RU2812477C2 (ru) * 2017-04-27 2024-01-30 Иммусофт Корпорейшн В-клетки для доставки терапевтических средств in vivo и их дозы

Also Published As

Publication number Publication date
EP1572124A4 (en) 2007-11-28
CA2451739A1 (en) 2003-01-09
JP4370161B2 (ja) 2009-11-25
CZ20033515A3 (cs) 2005-01-12
WO2003002065A2 (en) 2003-01-09
CN1636015A (zh) 2005-07-06
RU2004102520A (ru) 2005-06-10
US20050255124A1 (en) 2005-11-17
PL367526A1 (en) 2005-02-21
SK15762003A3 (sk) 2005-01-03
US20090258033A1 (en) 2009-10-15
WO2003002065A3 (en) 2007-04-19
NZ530632A (en) 2007-04-27
US20030138458A1 (en) 2003-07-24
EP1572124A2 (en) 2005-09-14
JP2005502611A (ja) 2005-01-27
HUP0400346A2 (en) 2007-08-28
CN1931365A (zh) 2007-03-21
JP2005298523A (ja) 2005-10-27
AU2002322358B2 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
RU2316347C2 (ru) Композиция для стимуляции иммунного ответа (варианты), способы ее получения, применения и способы стимуляции иммунного ответа с использованием этих композиций
AU2002322358A1 (en) HCV E1E2 vaccine compositions
EP1438074B1 (en) Adjuvant compositions
US20090098153A1 (en) Activation of HCV-specific T cells
US20110177110A1 (en) Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
US20050074465A1 (en) HCV fusion proteins with modified NS3 domains
EP1576125A2 (en) Activation of hcv-specific cells
CA2318744A1 (en) Genetic immunization with nonstructural proteins of hepatitis c virus
PL203526B1 (pl) Kompozycje zawieraj ace antygeny E1E2 wirusa zapalenia w atroby typu C (HCV), zastosowanie tych kompozycji i sposoby wytwarzania kompozycji
HK1095332B (en) Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
MM4A The patent is invalid due to non-payment of fees

Effective date: 20130629